January 2024

Dear Valued Partner,

In June 2023, we discontinued a subset of ACUVUE® OASYS with Transitions™ parameters to support our commitment to advancing innovation and improving availability of supply amongst more common ACUVUE® brands. To further this strategy, today we are writing to inform you of our decision to discontinue the remaining parameters of ACUVUE® OASYS with Transitions™. Effective March 8, 2024, diagnostic lenses will be discontinued. ACUVUE® OASYS with Transitions™ will remain available for purchase while supplies last until June 30, 2024, when the product will be fully discontinued.


Our top priority remains ensuring our products are available for the patients and customers around the globe who rely on us. We will continue to bring new innovations to market while in parallel making decisions to balance our existing portfolio to prioritize the greatest patient needs.

New or existing patients currently wearing ACUVUE® OASYS with Transitions™ and looking for premium daily disposable options, could be recommended **ACUVUE® OASYS 1-Day** for outstanding performance, including comfort powered by tears*,1, or **ACUVUE® OASYS MAX 1-Day** with the extra benefits of ~60% blue-violet light filtering*,2 and reduced tear film evaporation³. For patients who wish to stay in reusable lenses, they should be recommended **ACUVUE® OASYS 2-Week**. In 29 clinical studies posted on ClinicalTrials.gov, the ACUVUE® OASYS Brand family has never been beaten in comfort[‡].

You can return any ACUVUE® OASYS with Transitions™ product on hand up to 6 months after the discontinuation date.

Should you have questions regarding this notice, please speak with your Territory Account Manager.

On behalf of the Vision team at Johnson & Johnson Vision Care, thank you for your continued support of the ACUVUE® Brand.



Marcus Savoi General Manager Johnson & Johnson Vision Care, a Division of Johnson & Johnson (Canada) Inc.

Johnson&Johnson

1. JJV Data on File 2021. HydraLuxe® Technology Definition. 2. JJV Data on File 2022. TearStable™ Technology Definition. 3. JJV Data on File, 2022. CSM Subjective Responses ACUVUE® OASYS MAX 1-Day Contact Lenses- Retrospective Meta-analysis.

Important safety information: ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care, a division of Johnson & Johnson (Canada) Inc., by calling 1-800-267-5098 or by visiting inivisionpro.ca.

Transitions, the Transitions logo and Transitions Light Intelligent Technology are trademarks of Transitions Optical, Inc. used under license by Transitions Optical Limited and Johnson & Johnson Vision Care, Inc.

© Johnson & Johnson Vision Care, a division of Johnson & Johnson (Canada) Inc. 2024 2024PP04537

^{*}Designed to support the functions of the tear film

[‡]29 clinical studies posted on ClinicalTrials.gov, a website maintained by the NIH, evaluated subjective comfort as primary or secondary endpoint for ACUVUE® OASYS Brand 2-week family and daily disposable contact lens families vs. competitors' products as of October 31, 2023.

Filtering of HEV light by contact lenses has not been demonstrated to confer any health benefit to the user, including but not limited to retinal protection, protection from cataract progression, reduced eye strain, improved contrast, improved acuity, reduced glare, improved low light vision, or improved circadian rhythm/sleep cycle. The Eye Care Professional should be consulted for more information.